Moderna, Inc.
320 Bent Street
Cambridge
Massachusetts
02141
United States
Tel: 617-714-6500
Fax: 617-583-1998
Website: http://www.modernatx.com/
Email: info@modernatx.com
About Moderna, Inc.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.
Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.
162 articles with Moderna, Inc.
-
Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019
10/22/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2019 to report its third quarter 2019 financial results and provide a corporate update.
-
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
10/22/2019
mRNA-3927 is Moderna’s second rare disease program to receive Fast Track designation
-
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
10/2/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C.
-
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
9/30/2019
Moderna, Inc. announced the U.S. Food and Drug Administration has completed their review of the Investigational New Drug application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia and allowed it to proceed to clinic.
-
Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
9/26/2019
Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities
-
Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna
9/26/2019
Harvard University has established a multi-year research collaboration with the biotech company Moderna, Inc., with the goal of identifying and developing novel therapeutic approaches that could improve the lives of patients with immunological diseases
-
Moderna to Present at Upcoming Investor Conferences in October 2019
9/25/2019
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences
-
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
9/12/2019
Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults.
-
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
9/12/2019
Moderna, Inc. announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus vaccine.
-
BioSpace Movers & Shakers, Sept. 6
9/6/2019
Biopharma companies strengthen the C-suite and board of directors with these appointments. -
Moderna Appoints Tracey Franklin as Chief Human Resources Officer
9/4/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer
-
Moderna to Host R&D Day on September 12, 2019
8/29/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its third annual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 12 at the JW Marriott Essex House in New York City.
-
Moderna to Present at Upcoming Investor Conferences
8/27/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences
-
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
8/19/2019
Moderna, Inc., (Nasdaq: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.
-
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
8/7/2019
Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented
-
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
-
Moderna to Present at ROTH RNA Revolution Conference
7/10/2019
Lorence Kim, M.D., Chief Financial Officer will participate in the ROTH RNA Revolution Conference on July 17, 2019.
-
Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
6/18/2019
Moderna, Inc. announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET.
-
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
6/7/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference
-
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
6/1/2019
Moderna, Inc. announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors.